Minireviews
Copyright ©The Author(s) 2025.
World J Clin Cases. Jul 26, 2025; 13(21): 104723
Published online Jul 26, 2025. doi: 10.12998/wjcc.v13.i21.104723
Table 1 Conditions associated with high serum basal tryptase levels
Etiology
Diagnostic methods
Serum basal tryptase range
Incidence
Hereditary alpha tryptasemiaddPCR8-50 ng/mL≤ 67%
No disease is detectedExclusion diagnosisVariable≤ 23%
Renal failureGlomerular filtration rate < 60 mL/minute, elevated creatinine10-50 ng/mL≤ 16%
Systemic mastocytosisBone marrow aspiration, c-KIT D816V mutation by ddPCR, skin biopsy20-200 ng/mL≤ 5%
Other myeloid neoplasms, acute myeloid leukemia, myeloproliferative neoplasms, myeloid neoplasms with eosinophilia, myelodysplastic neoplasmsComplete blood count, bone marrow aspiration, molecular genetics, cytogenetics15-50 ng/mLRare
Hypereosinophilic syndromeBone marrow aspiration, molecular genetics, cytogenetics10-50 ng/mLRare
Chronic inflammatory diseases, rheumatoid arthritis, eosinophilic esophagitisRheumatological examinations, endoscopy, biopsy5-25 ng/mLRare
Table 2 Clinical findings in hereditary alpha tryptasemia
Clinical findings
Gastrointestinal symptomsNausea
Abdominal pain
Diarrhea
Vomiting
Dyspepsia
Neuropsychiatric findingsCognitive disorders (such as memory disorders)
Fatigue
Sleep disorders
Depressive disorders
Nervousness
Cutaneous and allergic symptomsSudden hot flushes
Pruritus
Rash, urticaria
PainMuscle pain
Headache
Joint pain
Other findingsSystemic sudden hypersensitivity reaction
Joint hypermobility
Table 3 Common indications for genetic testing for hereditary alpha tryptasemia
sBT level ≥ 8 ng/mL
Recurrent signs of MC activation with unclear etiology (such as idiopathic anaphylaxis)
Suspected SM with negative c-KIT D816V, but very high TPS level
SM or MCAS with severe mediator-related symptoms
Serum TPS value > 15.0 ng/mL without underlying mastocytosis or myeloid neoplasm
Familial clustering of systemic MC activation symptoms
Higher levels of sBT according to the degree of bone marrow mast cell infiltration
Diagnosed or suspected idiopathic or secondary MCAS